BeiGene Announces Ticker Change to ONC Effective January 2025

BGNE Stock  USD 181.89  2.79  1.51%   
About 55% of BeiGene's investor base is interested to short. The analysis of the overall investor sentiment regarding BeiGene suggests that many traders are impartial. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
  
BeiGene shares rose approximately 1.6 percent in pre-market trading, reaching 180.53. The company announced a significant change to its stock ticker on the Nas

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

BeiGene Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards BeiGene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

BeiGene Fundamental Analysis

We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

BeiGene is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

BeiGene Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.

Peers

BeiGene Related Equities

AKROAkero Therapeutics   1.16   
0%
20.0%
BMRNBiomarin Pharmaceutical   0.19   
3.0%
0%
INCYIncyte   0.47   
8.0%
0%
KRYSKrystal Biotech   0.75   
13.0%
0%
APLSApellis Pharmaceuticals   0.85   
15.0%
0%
LEGNLegend Biotech   0.88   
15.0%
0%
IONSIonis Pharmaceuticals   1.16   
20.0%
0%
ASNDAscendis Pharma   2.00   
35.0%
0%
IMABI Mab   2.22   
39.0%
0%
BPMCBlueprint Medicines   2.42   
43.0%
0%
TVTXTravere Therapeutics   2.81   
50.0%
0%
ARWRArrowhead Pharmaceuticals   2.92   
52.0%
0%
IMVTImmunovant   4.82   
85.0%
0%
PCVXVaxcyte   5.61   
100.0%
0%

Complementary Tools for BeiGene Stock analysis

When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk